HIGHLIGHTS: The overall response rate to neoadjuvant endocrine therapy (NET) was 54.55%.The eight patients proposed to tumour's downstage, after 9.71 months of NET, preserved their breast.In the group which achieved response, 10.28 months was the mean time to accomplish it.Even patients who had the worst outcome only began to suffer latter in the course of therapy.NET can be done beyond the conventional 3-4 months to allow additional downstage of the tumour. BACKGROUND: The aim of this study is to evaluate if the extension of neoadjuvant endocrine therapy (NET), beyond the conventional time, allows additional downstage of the tumour, in order to perform a breast conservative surgery (BCS), and to analyze if it is a good option for long-term control in patients who refuse or are unfit for surgery. PATIENTS AND METHODS: We retrospectively reviewed a database containing all patients treated in our institution with NET. All included patients were post-menopausal with primary local disease. The type of response obtained was assessed using modified RECIST criteria. RESULTS: Thirty-three patients were included. Two patients had tumours with 90% expression of oestrogen receptors and all the others had 100%. The tumour size in the largest diameter was 6.51 cm before treatment and 5.18 cm after. Eighteen patients achieved a partial response after 10.28 months of therapy. Patients that were proposed to downstage the tumour performed 9.71 months of therapy until surgery and all were submitted to BCS. Progression occurred after 27.5 months. CONCLUSION: Endocrine therapy is a feasible option for a longer time to allow additional downstage of the tumour and is a good solution in patients who refuse or are unfit for surgery. Copyright 2017 PBJ-Associação Porto Biomedical/Porto Biomedical Society.
HIGHLIGHTS: The overall response rate to neoadjuvant endocrine therapy (NET) was 54.55%.The eight patients proposed to tumour's downstage, after 9.71 months of NET, preserved their breast.In the group which achieved response, 10.28 months was the mean time to accomplish it.Even patients who had the worst outcome only began to suffer latter in the course of therapy.NET can be done beyond the conventional 3-4 months to allow additional downstage of the tumour. BACKGROUND: The aim of this study is to evaluate if the extension of neoadjuvant endocrine therapy (NET), beyond the conventional time, allows additional downstage of the tumour, in order to perform a breast conservative surgery (BCS), and to analyze if it is a good option for long-term control in patients who refuse or are unfit for surgery. PATIENTS AND METHODS: We retrospectively reviewed a database containing all patients treated in our institution with NET. All included patients were post-menopausal with primary local disease. The type of response obtained was assessed using modified RECIST criteria. RESULTS: Thirty-three patients were included. Two patients had tumours with 90% expression of oestrogen receptors and all the others had 100%. The tumour size in the largest diameter was 6.51 cm before treatment and 5.18 cm after. Eighteen patients achieved a partial response after 10.28 months of therapy. Patients that were proposed to downstage the tumour performed 9.71 months of therapy until surgery and all were submitted to BCS. Progression occurred after 27.5 months. CONCLUSION: Endocrine therapy is a feasible option for a longer time to allow additional downstage of the tumour and is a good solution in patients who refuse or are unfit for surgery. Copyright 2017 PBJ-Associação Porto Biomedical/Porto Biomedical Society.
Entities:
Keywords:
Breast cancer; Breast conserving surgery; Endocrine therapy; Estrogen receptor-positive; Neoadjuvant treatment
Authors: C Palmieri; S Cleator; L S Kilburn; S B Kim; S-H Ahn; M Beresford; G Gong; J Mansi; E Mallon; S Reed; K Mousa; L Fallowfield; M Cheang; J Morden; K Page; D S Guttery; B Rghebi; L Primrose; J A Shaw; A M Thompson; J M Bliss; R C Coombes Journal: Breast Cancer Res Treat Date: 2014-11-14 Impact factor: 4.872
Authors: E Senkus; S Kyriakides; S Ohno; F Penault-Llorca; P Poortmans; E Rutgers; S Zackrisson; F Cardoso Journal: Ann Oncol Date: 2015-09 Impact factor: 32.976
Authors: Frederico Leal; Vitor Teixeira Liutti; Vivian Castro Antunes dos Santos; Maximiliano Augusto Novis de Figueiredo; Ligia Traldi Macedo; José Augusto Rinck Junior; Andre Deeke Sasse Journal: Breast Date: 2015-04-07 Impact factor: 4.380
Authors: Duveken B Y Fontein; Ayoub Charehbili; Johan W R Nortier; Elma Meershoek-Klein Kranenbarg; Judith R Kroep; H Putter; Yvonne van Riet; Grard A P Nieuwenhuijzen; Bart de Valk; Jetske M Meerum Terwogt; Gijs D Algie; Gerrit-Jan Liefers; Sabine Linn; Cornelis J H van de Velde Journal: Eur J Cancer Date: 2014-06-23 Impact factor: 9.162
Authors: Luigi Cataliotti; Aman U Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsuka; Katarina Petrakova; Pierre Dube; Celia Tosello de Oliveira Journal: Cancer Date: 2006-05-15 Impact factor: 6.860
Authors: S J Johnston; F S Kenny; B M Syed; J F R Robertson; S E Pinder; L Winterbottom; I O Ellis; R W Blamey; K L Cheung Journal: Ann Oncol Date: 2012-02-21 Impact factor: 32.976
Authors: A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2013-08-04 Impact factor: 32.976